UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 0.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,936,957 shares of the medical equipment provider’s stock after selling 41,428 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Boston Scientific were worth $1,042,839,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the business. Claret Asset Management Corp grew its stake in shares of Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC grew its stake in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 103 shares during the period. Outfitters Financial LLC grew its stake in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after acquiring an additional 110 shares during the period. Fayez Sarofim & Co grew its stake in shares of Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after acquiring an additional 111 shares during the period. Finally, Natural Investments LLC grew its stake in shares of Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after acquiring an additional 112 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Robert W. Baird set a $70.00 price target on Boston Scientific in a research note on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Truist Financial cut their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $85.08.
Boston Scientific Stock Performance
Shares of BSX opened at $46.83 on Friday. The company has a market cap of $69.60 billion, a PE ratio of 19.59, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a 50-day moving average price of $56.37 and a 200-day moving average price of $74.95. Boston Scientific Corporation has a 12-month low of $45.99 and a 12-month high of $109.50.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.
Boston Scientific declared that its Board of Directors has authorized a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.
Insider Activity at Boston Scientific
In other news, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.
Boston Scientific News Roundup
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
- Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
- Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
- Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
- Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
- Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
- Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Further Reading
- Five stocks we like better than Boston Scientific
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
